Saronic Raises $175 Million In Series B Funding, Valuing Company At $1 Billion

Funding will accelerate Saronic's growth and further scale production of its autonomous surface vessels for the U.S. Navy and its allies

AUSTIN, Texas, July 19, 2024 /PRNewswire/ -- Saronic, a defense technology leader that designs and manufactures autonomous surface vessels (ASVs), today announced a $175 million Series B raise placing the company's valuation at $1 billion. The funding round was led by Andreessen Horowitz (a16z), with participation from both new and existing investors, including 8VC, Caffeinated Capital, Elad Gil, and NightDragon, among others.

Saronic is redefining maritime superiority for the U.S. Navy and its allies by delivering the most effective and advanced ASVs at the speed and scale needed to meet the rapidly growing needs of the Joint Force. Saronic's ASVs are designed to serve as a force multiplier for the existing Fleet, working alongside manned systems to allow naval forces to go farther and do more with less risk to life and mission.

"We are creating an entirely new capability for the maritime domain, one that delivers naval power without the costs and delays of a shipyard," said Saronic CEO Dino Mavrookas. "As the future of naval warfare will rely on manned and unmanned teaming, we must build solutions that easily integrate into the existing fleet and can be produced at scale to meet any emerging threat. We are grateful to our investment partners who believe so strongly in Saronic's ability to meet that need."

Saronic's investor group is composed of firms committed to ensuring that the U.S. military maintains its decisive advantage in the face of an increasingly complex and competitive global threat landscape through the integration of advanced technology and innovative capabilities that truly meet the needs of the warfighter.

"Our nation's future depends on us continuing to build and deploy the best, most innovative technology" said Katherine Boyle, General Partner at a16z. "Saronic is developing the solutions we need to protect the warfighter and stay ahead of our adversaries, and we are proud to support their continued growth."

This new investment will accelerate Saronic's growth both domestically and internationally. At home, it will allow further expansion of Saronic's in-house manufacturing capabilities and enable increased production of all its ASV models. Additionally, it will advance the research and development of new autonomous capabilities for naval and maritime forces, including increased technology and payload integration with government and commercial partners. Internationally, this investment will support Saronic's expansion to more fully serve U.S. allies and partners in key markets.

"To deter China and other adversaries, the United States and our allies must bring intelligent, autonomous new capabilities to naval warfare," said Alex Moore, Partner at 8VC. "Saronic delivers these capabilities on a relevant scale and timeline, and has enlisted the top engineers and operators in the industry."

Saronic's family of ASVs includes Spyglass (6'), Cutlass (14') and Corsair, its largest model, which is currently in development and testing. Each vessel features integrated autonomous capabilities to meet a customer's specific requirements and can carry diverse payloads in communication- and GPS-denied environments. Through the vertical integration of hardware and software as well as the use of a Modular Open Systems Architecture (MOSA), Saronic's ASVs deliver greater interoperability at a price point that makes them attritable. Having a cost-effective capability that can be deployed without putting human operators in harm's way increases the survivability of the fleet and enables commanders to engage in situations where the risk is too high to deploy a traditional manned system.

For more information about Saronic, please visit: https://www.saronic.com.

Media Contact: Press@saronic.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/saronic-raises-175-million-in-series-b-funding-valuing-company-at-1-billion-302201280.html

SOURCE Saronic

First published on Fri, Jul 19, 2024

Liked what you read? That’s only the tip of the tech iceberg!

Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!

Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.

Dive into TechDogs' treasure trove today and Know Your World of technology like never before!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Rona Therapeutics LongRiver Investments Clinical Stage Pioneering Platform Nucleic Acid Innovative Drug Platform LongRiver Investments

Join The Discussion

Biotechnology